Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy
Mary Barber, Michael J. Mauro, Javid J. Moslehi
Hematology (2017) Vol. 2017, Iss. 1, pp. 110-114
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal (2022) Vol. 43, Iss. 41, pp. 4229-4361
Open Access | Times Cited: 1579
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, et al.
European Heart Journal - Cardiovascular Imaging (2022) Vol. 23, Iss. 10, pp. e333-e465
Open Access | Times Cited: 211
Chronic myeloid leukaemia
Jorge E. Cortés, Carolina Pavlovsky, Susanne Saußele
The Lancet (2021) Vol. 398, Iss. 10314, pp. 1914-1926
Closed Access | Times Cited: 126
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, et al.
Leukemia (2023) Vol. 37, Iss. 3, pp. 617-626
Open Access | Times Cited: 83
How I treat chronic myeloid leukemia in children and adolescents
Nobuko Hijiya, Meinolf Suttorp
Blood (2019) Vol. 133, Iss. 22, pp. 2374-2384
Open Access | Times Cited: 115
Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia
Onyee Chan, Chetasi Talati, Leidy Isenalumhe, et al.
Blood Advances (2020) Vol. 4, Iss. 3, pp. 530-538
Open Access | Times Cited: 81
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer
Anja Karlstaedt, Javid J. Moslehi, Rudolf A. de Boer
Nature Reviews Cardiology (2022) Vol. 19, Iss. 6, pp. 414-425
Open Access | Times Cited: 57
Sphingosine-1-Phosphate Receptor 1 Activity Promotes Tumor Growth by Amplifying VEGF-VEGFR2 Angiogenic Signaling
Vijay Avin Balaji Ragunathrao, Mumtaz Anwar, Md Zahid Akhter, et al.
Cell Reports (2019) Vol. 29, Iss. 11, pp. 3472-3487.e4
Open Access | Times Cited: 57
Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option
Jeffrey H. Lipton, Tim H. Brümmendorf, Carlo Gambacorti‐Passerini, et al.
Blood Reviews (2022) Vol. 56, pp. 100968-100968
Open Access | Times Cited: 35
Chronic myeloid leukaemia: Biology and therapy
Yun Wang, Zhi-Jian Liang, Robert Peter Gale, et al.
Blood Reviews (2024) Vol. 65, pp. 101196-101196
Closed Access | Times Cited: 7
Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care
Moussab Damlaj, Riad El Fakih, Shahrukh K. Hashmi
Blood Reviews (2018) Vol. 33, pp. 63-73
Closed Access | Times Cited: 50
Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies
Fang Cheng, Qiling Xu, Qiang Li, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 12
Chronic myeloid leukaemia
David T O Yeung, Timothy P. Hughes
(2025), pp. 630-651
Closed Access
Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Carolina Pavlovsky, Onyee Chan, Chetasi Talati, et al.
Future Oncology (2018) Vol. 15, Iss. 3, pp. 257-269
Closed Access | Times Cited: 35
The role of bosutinib in the treatment of chronic myeloid leukemia
Carlo Gambacorti‐Passerini, Philipp le Coutre, Rocco Piazza
Future Oncology (2019) Vol. 16, Iss. 2, pp. 4395-4408
Open Access | Times Cited: 31
How to manage CML patients with comorbidities
Jorge E. Cortés
Blood (2020) Vol. 136, Iss. 22, pp. 2507-2512
Closed Access | Times Cited: 28
Management of Chronic Myeloid Leukemia in Children and Young Adults
Maegan Ford, Michael J. Mauro, Catherine Aftandilian, et al.
Current Hematologic Malignancy Reports (2022) Vol. 17, Iss. 5, pp. 121-126
Open Access | Times Cited: 18
A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia
Rasha Kaddoura, Wafer Dabdoob, Khalid Ahmed, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 10
Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation
Jesus Paez‐Mayorga, Andrew L. Chen, Sivareddy Kotla, et al.
Frontiers in Cardiovascular Medicine (2018) Vol. 5
Open Access | Times Cited: 31
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors
Matthew R. Fleming, Ling Xiao, Klarissa D. Jackson, et al.
Circulation Research (2021) Vol. 128, Iss. 12, pp. 1973-1987
Open Access | Times Cited: 22
The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia
Adrian Minson, Katherine D. Cummins, Lucy C. Fox, et al.
Blood Advances (2019) Vol. 3, Iss. 7, pp. 1084-1091
Open Access | Times Cited: 23
Survivorship Care of Older Adults With Cancer: Priority Areas for Clinical Practice, Training, Research, and Policy
Erin E. Kent, Eliza M. Park, William A. Wood, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 19, pp. 2175-2184
Open Access | Times Cited: 19
An association between Dasatinib, elevated left atrial pressure and pleural effusion
Sean Tan, Diva Baggio, Kylie Porch, et al.
International Journal of Cardiology (2024) Vol. 410, pp. 132216-132216
Closed Access | Times Cited: 2
Understanding cardiac events in breast cancer (UCARE): pilot cardio-oncology assessment and surveillance pathway for breast cancer patients
Michael J. Cronin, Aoïfe Lowery, Veronica McInerney, et al.
Breast Cancer Research and Treatment (2024) Vol. 207, Iss. 2, pp. 283-291
Open Access | Times Cited: 2
Cancer and Heart Failure: Dangerous Liaisons
D. Bertolini, Carmine Pizzi, Erwan Donal, et al.
Journal of Cardiovascular Development and Disease (2024) Vol. 11, Iss. 9, pp. 263-263
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top